Owen A Ross
Ross, Owen A.
VIAF ID: 4241148209332500460000 (Personal)
Permalink: http://viaf.org/viaf/4241148209332500460000
Preferred Forms
- 100 0 _ ‡a Owen A Ross
-
-
-
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Deep brain stimulation for levodopa-refractory benign tremulous parkinsonism | |
LINGO1 rs9652490 is associated with essential tremor and Parkinson disease | |
Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain | |
Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. | |
Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia | |
LRRK2 mutations are not common in Alzheimer's disease. | |
Lrrk2 R1628P in non-Chinese Asian races | |
MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features | |
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. | |
Mitochondrial DNA damage in lymphocytes: a role in immunosenescence? | |
Mitochondrial J haplogroup is associated with lower blood pressure and anti-oxidant status: findings in octo/nonagenarians from the BELFAST Study | |
Mitochondrial membrane protein-associated neurodegeneration. | |
Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders | |
Multiple system atrophy and apolipoprotein E. | |
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study | |
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity | |
NOTCH3 variants and risk of ischemic stroke | |
Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease. | |
A novel de novo pathogenic mutation in the CACNA1A gene | |
Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration | |
A novel tau mutation, p.K317N, causes globular glial tauopathy | |
Occurrence of Crohn's disease with Parkinson's disease. | |
PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease | |
Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons. | |
Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations | |
(Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation | |
Patient-control association study of the Leucine-Rich repeat kinase 2 | |
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease | |
The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity | |
PINK1 Phosphorylates MIC60/Mitofilin to Control Structural Plasticity of Mitochondrial Crista Junctions. | |
Plasma neurofilament light predicts mortality in patients with stroke | |
Principal-component analysis for assessment of population stratification in mitochondrial medical genetics | |
Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants | |
Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy | |
Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease. | |
Relationships between lewy and tau pathologies in 375 consecutive non-Alzheimer's olfactory bulbs. | |
Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci | |
Reply: GIGYF2 variants are not associated with Parkinson's disease in Italy | |
Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. | |
Reply to: SNCA variants are associated with increased risk of multiple system atrophy | |
Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies | |
Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease | |
Rozpoznawanie i leczenie otępienia z ciałami Lewy'ego : czwarte stanowisko DLB Consortium = Diagnosis and management of dementia with Lewy bodies : fourth consensus report of the DLB Consortium | |
Rozpoznawanie i leczenie otępienia z ciałami Lewy'ego / Ian G. McKeith [i inni] // MP Medycna Praktyczna. Neurologia. - 5 (47) 2017, strony 21-39. | |
Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. | |
Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples | |
Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia | |
Sex and age interact to determine clinicopathologic differences in Alzheimer's disease. | |
Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy | |
SLC1A2 rs3794087 does not associate with essential tremor | |
SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia | |
Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration | |
Systematic analysis of dark and camouflaged genes: disease-relevant genes hiding in plain sight: Supplemental figures | |
THAL AMYLOID PHASE: CLINICOPATHOLOGIC AND PIB-PET IMPLICATIONS OF AD PATHOPHYSIOLOGY | |
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease | |
TREM2 p.R47H substitution is not associated with dementia with Lewy bodies | |
TREM2 R47H variant and risk of essential tremor: a cross-sectional international multicenter study | |
The ups and downs of alpha-synuclein mRNA expression. | |
Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway | |
VPS35 and DNAJC13 disease-causing variants in essential tremor | |
VPS35 Mutations in Parkinson Disease | |
Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1. | |
α-synuclein genetic variability: A biomarker for dementia in Parkinson disease |